ROCO
4132
Market cap15mUSD
Apr 09, Last price
3.47TWD
Name
Golden Biotechnology Corp
Chart & Performance
P/E
—
P/S
12.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.55%
Rev. gr., 5y
-13.25%
Revenues
41m
-35.49%
Net income
-361m
L-0.26%
CFO
-263m
L-3.03%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||